

Washington University School of Medicine Digital Commons@Becker

Open Access Publications

2017

Circulating resistin levels and risk of multiple myeloma in three prospective cohorts

Loredana Santo
National Cancer Institute

Lauren R. Teras
American Cancer Society

Graham G. Giles
Cancer Council Victoria

Stephanie J. Weinstein
National Cancer Institute

Demetrius Albanes
National Cancer Institute

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation

Santo, Loredana; Teras, Lauren R.; Giles, Graham G.; Weinstein, Stephanie J.; Albanes, Demetrius; Wang, Ye; Pfeiffer, Ruth M.; Lan, Qing; Rothman, Nathaniel; Birmann, Brenda M.; Colditz, Graham A.; Pollak, Michael N.; Purdue, Mark P.; and Hofmann, Jonathan N., "Circulating resistin levels and risk of multiple myeloma in three prospective cohorts." *British Journal of Cancer*. 117,8. 1241-1245. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/6324

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.

Authors

Loredana Santo, Lauren R. Teras, Graham G. Giles, Stephanie J. Weinstein, Demetrius Albanes, Ye Wang, Ruth M. Pfeiffer, Qing Lan, Nathaniel Rothman, Brenda M. Birmann, Graham A. Colditz, Michael N. Pollak, Mark P. Purdue, and Jonathan N. Hofmann

Keywords: multiple myeloma; resistin; prospective cohorts

Circulating resistin levels and risk of multiple myeloma in three prospective cohorts

Loredana Santo¹, Lauren R Teras², Graham G Giles³, Stephanie J Weinstein¹, Demetrius Albanes¹, Ye Wang^{4,5}, Ruth M Pfeiffer¹, Qing Lan¹, Nathaniel Rothman¹, Brenda M Birmann^{6,7}, Graham A Colditz^{8,9}, Michael N Pollak^{4,5}, Mark P Purdue¹ and Jonathan N Hofmann^{*1}

¹Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA; ²American Cancer Society, Atlanta, GA 30303, USA; ³Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, VIC 3004, Australia; ⁴Department of Oncology, McGill University, Montreal, QC H3T 1E2, Canada; ⁵Segal Cancer Centre, Jewish General Hospital, Montreal, QC H3T 1E2, Canada; ⁶Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; ⁷Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; ⁸Department of Surgery and Alvin J. Siteman Cancer Center, Washington University School of Medicine and Barnes Jewish Hospital, St Louis, MO 63110, USA and ⁹Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA 02115, USA

Background: Resistin is a polypeptide hormone secreted by adipose tissue. A prior hospital-based case–control study reported serum resistin levels to be inversely associated with risk of multiple myeloma (MM). To date, this association has not been investigated prospectively.

Methods: We measured resistin concentrations for pre-diagnosis peripheral blood samples from 178 MM cases and 358 individually matched controls from three cohorts participating in the MM cohort consortium.

Results: In overall analyses, higher resistin levels were weakly associated with reduced MM risk. For men, we observed a statistically significant inverse association between resistin levels and MM (odds ratio, 0.44; 95% confidence interval (CI) 0.24–0.83 and 0.54; 95% CI 0.29–0.99, for the third and fourth quartiles, respectively, vs the lowest quartile; $P_{\text{trend}} = 0.03$). No association was observed for women.

Conclusions: This study provides the first prospective evidence that low circulating resistin levels may be associated with an increased risk of MM, particularly for men.

Multiple myeloma (MM), a plasma cell disease, was newly diagnosed in an estimated 24 280 individuals in 2016 in the United States (Teras *et al*, 2016). Besides well-established risk factors, such as male sex, older age, African ancestry, and a family history of haematological malignancies (Baris *et al*, 2013), obesity has been shown to increase MM risk (Teras *et al*, 2014). The association between obesity and MM may be attributable in part to altered levels of various adipokines (e.g., adiponectin, leptin, and resistin) secreted by adipose tissue (Dalamaga *et al*, 2009). We have recently shown that the risk of MM is increased for individuals with low pre-diagnosis circulating levels of adiponectin

(Hofmann *et al*, 2016), but not of leptin (Hofmann *et al*, 2012). The potential role of resistin in MM development is poorly understood. An increased risk of MM for individuals with low serum levels of resistin was observed by one small hospital-based case–control study (73 MM cases and 73 controls) (Dalamaga *et al*, 2009). To our knowledge, the relationship between resistin and MM has not been evaluated prospectively. Using a nested case–control study involving three cohorts participating in the MM cohort consortium, we investigated whether pre-diagnosis circulating levels of resistin were associated with future MM risk.

*Correspondence: Dr JN Hofmann; E-mail: hofmannjn@mail.nih.gov

Received 31 January 2017; revised 11 July 2017; accepted 21 July 2017; published online 22 August 2017

© 2017 Cancer Research UK. All rights reserved 0007–0920/17

MATERIALS AND METHODS

Cases ($n=178$) and controls ($n=358$) were selected from the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC), the Cancer Prevention Study II (CPS-II), and the Melbourne Collaborative Cohort Study (MCCS) (ATBC, 1994; Calle *et al*, 2002; Giles and English, 2002). Participating cohorts received Institutional Review Board approval from their respective institutions. We selected cases with a primary incident diagnosis of MM (ICDA = 203; ICD-O-2-M = 9731, 9732, and 9830; or ICD-O-3-M = 9731–9734) and a stored blood sample collected ≥ 3 months before MM diagnosis. Controls with no history of cancer were individually matched to cases based on cohort of origin, birth year (± 12 months), sex, type of blood sample (serum, plasma-heparin, and plasma-EDTA), date of blood collection (± 2 months), and fasting status at blood draw with a 2:1 ratio as previously described (Birmann *et al*, 2012; Hofmann *et al*, 2016). All of the cases and controls included in this investigation were non-Hispanic whites.

Circulating levels of resistin were measured in duplicate by ELISA (Human Resistin Quantikine ELISA by R&D Systems, Inc., Minneapolis, MN, USA). Assays were performed in the laboratory of MNP at McGill University. The lower limit of detection was 0.156 ng ml^{-1} . Samples from MM patients and their matched controls were analysed in the same batch, and blinded quality control (QC) replicates were included in each batch as previously described (Hofmann *et al*, 2016). The overall intraclass correlation coefficient was 0.86, and the coefficient of variation for pooled QC specimens was 6.1%, with no evidence of laboratory drift across cohorts.

We used the Wilcoxon rank-sum test to assess differences in resistin levels between cases and controls. For our main analyses, we performed cohort- and sex-specific corrections of resistin values to reduce the impact of cohort-related variability, and to account for differences between men and women within and across the participating studies (Birmann *et al*, 2012; Hofmann *et al*, 2016) (Supplementary Methods). Odds ratios (ORs) and 95% confidence intervals (95% CIs) for risk of MM were computed using conditional logistic regression models with levels of resistin categorised into quartiles based on the distribution among controls. We performed analyses stratified by sex, time to MM diagnosis, and age at sample collection using conditional logistic regression models, and analyses stratified by BMI categories using unconditional logistic regression models adjusted for matching factors. Multiplicative interaction was assessed using Wald tests. Study-specific ORs and 95% CIs were estimated comparing resistin levels above and below the median (based on the distribution in controls); we conducted a meta-analysis using both fixed and random effects models, and assessed heterogeneity across cohorts using the Cochran Q-test and the I^2 statistic. For all analyses, findings were considered statistically significant if the two-sided P -value was < 0.05 .

RESULTS

Cases and controls had similar distributions of sex, age at the blood draw, and type of blood sample (Table 1). Cohort- and sex-corrected resistin levels were somewhat lower among cases compared with controls; these differences were statistically significant among men ($P=0.006$, Wilcoxon rank-sum test) but not among women ($P=0.22$). Levels of resistin and total adiponectin (measured previously) were not correlated among cases or controls (Spearman's correlation coefficients of -0.07 and 0.09 , respectively; $P \geq 0.1$). In multivariate analyses of the pooled controls, circulating levels of resistin were higher among men compared with women, but were not associated with age or BMI (Supplementary Table S1).

Table 1. Selected characteristics of cases and controls

Characteristic	Cases ^a	Controls ^a
Patients	178 (100)	358 (100)
Cohort		
ATBC	59 (33.2)	117 (32.7)
CPS-II	67 (37.6)	135 (37.7)
MCCS	52 (29.2)	106 (29.6)
Sex		
Female	49 (27.5)	100 (27.9)
Male	129 (72.5)	258 (72.1)
Mean (s.d.) age at blood draw	63.0 (7.8)	63.0 (7.8)
Mean (s.d.) BMI at blood draw, kg/m^2	26.9 (4.0)	26.5 (4.2)
Type of blood sample		
EDTA	67 (37.6)	135 (37.7)
Heparin plasma	52 (29.2)	106 (29.6)
Serum	59 (33.2)	117 (32.7)
Time from blood draw to diagnosis		
< 7 years	85 (47.8)	
≥ 7 years	93 (52.3)	
Median resistin concentration ^b (IQR)		
Overall	5.47 (4.08–7.11)	5.82 (4.47–7.37)
Female	6.24 (5.11–8.44)	5.88 (4.48–7.66)
Male	5.20 (3.93–6.46) ^c	5.82 (4.44–7.33)

Abbreviations: ATBC = Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; BMI = body mass index; CPS-II = the Cancer Prevention Study II; IQR = interquartile range; MCCS = Melbourne Collaborative Cohort Study.
^aReported as N (%) unless otherwise noted.
^bOn the basis of corrected resistin levels in ng ml^{-1} (Supplementary Methods).
^cWilcoxon two-sample test $P=0.006$.

Higher resistin levels were weakly associated with a reduced risk of MM in overall analyses, although the observed associations were not statistically significant (Table 2). Findings were similar after adjusting for BMI and adiponectin levels. Among a subset of participants from the ATBC and MCCS cohorts with available data on markers related to IGF-1 and interleukin (IL)-6 pathways (Birmann *et al*, 2012), we found that results were essentially unchanged after adjustment for these other analytes (data not shown). Among men, we observed a statistically significant reduced risk of MM among those with higher levels of resistin (ORs of 0.44 (95% CI 0.24–0.83) and 0.54 (0.29–0.99) for the third and fourth quartiles, respectively, *vs* the lowest quartile; $P_{\text{trend}}=0.026$). This association remained after adjusting for BMI and adiponectin levels (data not shown). In contrast, resistin levels were not associated with MM risk among women ($P_{\text{interaction}}=0.12$). In other stratified analyses, we did not observe statistically significant differences in the ORs across strata for time to MM diagnosis, BMI category, or age at blood collection. Our main findings were essentially unchanged after excluding high outlying resistin levels and when quartiles were based on the overall distribution of resistin levels among controls rather than the cohort- and sex-corrected levels.

Cohort- and sex-specific results are shown in Figure 1. Among men, there was some evidence of heterogeneity across cohorts ($I^2=62.3\%$, $P=0.071$). The association was strongest among men in the MCCS (OR 0.12, 95% CI 0.026–0.53), although non-significant inverse associations were also observed among men in the other cohorts (ORs of 0.63 (0.30–1.34) and 0.79 (0.42–1.48) in CPS-II and ATBC, respectively). Among women, ORs were elevated but not statistically significant in both CPS-II and MCCS.

DISCUSSION

This study is, to our knowledge, the first prospective investigation of circulating levels of resistin and risk of MM. Our findings

Table 2. Circulating resistin levels and risk of MM, overall and stratified by selected characteristics

	Quartile (Q)								P _{trend}	P _{int} ^a
	Q1		Q2		Q3		Q4			
	N _{cases}	OR (95% CI)	N _{cases}	OR (95% CI)	N _{cases}	OR (95% CI)	N _{cases}	OR (95% CI)		
Crude	55	1.0 (ref)	48	0.87 (0.53–1.44)	33	0.61 (0.36–1.03)	42	0.75 (0.45–1.25)	0.20	
Adjusted for BMI	54	1.0 (ref)	48	0.87 (0.52–1.46)	32	0.60 (0.35–1.02)	41	0.76 (0.45–1.29)	0.24	
Adjusted for BMI and adiponectin	54	1.0 (ref)	48	0.86 (0.51–1.43)	32	0.59 (0.35–1.01)	41	0.76 (0.45–1.29)	0.24	
By sex										
Female	9	1.0 (ref)	11	1.27 (0.44–3.64)	12	1.56 (0.55–4.45)	17	1.82 (0.66–5.00)	0.23	0.12
Male	46	1.0 (ref)	37	0.77 (0.43–1.38)	21	0.44 (0.24–0.83)	25	0.54 (0.29–0.995)	0.03	
By time to MM diagnosis										
< 7 years	28	1.0 (ref)	20	0.63 (0.29–1.37)	14	0.41 (0.18–0.90)	23	0.61 (0.30–1.25)	0.21	0.47
≥ 7 years	27	1.0 (ref)	28	1.14 (0.58–2.26)	19	0.92 (0.45–1.87)	19	0.87 (0.41–1.86)	0.61	
By BMI _{category} ^b										
< 25 kg m ⁻²	23	1.0 (ref)	12	0.59 (0.25–1.36)	13	0.68(0.29–1.57)	13	0.61 (0.27–1.40)	0.30	0.45
25–29.9 kg m ⁻²	19	1.0 (ref)	26	0.98 (0.44–2.18)	17	0.60 (0.26–1.42)	16	0.62 (0.26–1.52)	0.20	
≥ 30 kg m ⁻²	12	1.0 (ref)	10	1.31 (0.43–3.95)	2	0.23 (0.04–1.21)	12	1.47 (0.46–4.64)	0.91	
By age at blood draw										
< 65 years	34	1.0 (ref)	31	0.86 (0.45–1.64)	17	0.55 (0.27–1.13)	18	0.61 (0.29–1.26)	0.12	0.76
≥ 65 years	21	1.0 (ref)	17	0.87 (0.38–1.97)	16	0.64 (0.29–1.41)	24	0.89 (0.42–1.91)	0.78	

Abbreviations: BMI = body mass index; CI = confidence interval; MM = multiple myeloma; OR = odds ratio; P_{int} = P_{interaction}; ref = reference. Odds ratios and 95% CI were estimated using conditional logistic regression models, unless otherwise noted. Quartile cut-off points were defined on the basis of the distribution of cohort- and sex-adjusted resistin levels among controls, as follows: Q1 ≤ 4.59 ng ml⁻¹, Q2 4.60–5.82 ng ml⁻¹, Q3 5.83–7.37 ng ml⁻¹, and Q4 ≥ 7.38 ng ml⁻¹.
^aTests of multiplicative interaction were based on the same models as those used for the stratified analyses and were performed using Wald tests.
^bUnconditional logistic regression adjusted for cohort, age, sex and fasting status.




Figure 1. Cohort-specific and meta-analysis summary ORs and 95% CIs for the association between circulating resistin levels (above vs below the median) and MM risk among men (upper panel) and women (lower panel).

suggest that high pre-diagnosis circulating resistin levels are associated with a reduced future risk of MM development, in particular among men. These results are consistent with findings from a prior hospital-based case-control study (Dalamaga *et al*, 2009). Although we did not find evidence of an association among women, our investigation included relatively few female MM cases and thus we had limited statistical power for this subgroup analysis. Our findings may also reflect true differences by sex in the biological activity of resistin due to interaction with sex or metabolic hormones or other inflammatory markers that are differentially expressed in men and women (Dalamaga *et al*, 2013). We also observed a somewhat stronger

association during the time period closer to MM diagnosis, which may reflect altered resistin expression related to onset or progression of monoclonal gammopathy of undetermined significance.

Resistin increases nuclear factor kappa B-related monocyte expression of pro-inflammatory cytokines such as IL-6 (Tilg and Moschen, 2006; Lee *et al*, 2014). Thus, the observed increased risk of MM in males with lower levels of resistin might reflect a compensatory effect of resistin or a negative feedback loop following the production of IL-6 and/or other cytokines with known effects on proliferation and survival of MM cells (Dalamaga *et al*, 2009). Alternatively, previous studies have shown that TNF-α

decreases resistin secretion in murine models (Rajala *et al*, 2002). If TNF- α , a well-characterised pro-inflammatory cytokine that stimulates MM cell proliferation (Hideshima *et al*, 2001), also acts as a negative regulator of resistin in humans, this action may explain the observed inverse association between pre-diagnosis resistin levels and MM risk. This hypothesis is corroborated by increased resistin levels in MM patients after treatment with thalidomide, a TNF- α inhibitor (Reseland *et al*, 2009).

Resistin deregulation in obesity-related inflammatory conditions may also result from altered expression by non-adipocyte inflammatory cells, such as macrophages, in adipose tissue (Patel *et al*, 2003; Curat *et al*, 2006). While some studies have observed elevated levels of resistin among individuals with higher BMI or visceral fat area (Yannakoulia *et al*, 2003; Reseland *et al*, 2009), other studies found no association (Lee *et al*, 2003; Dalamaga *et al*, 2013). The lack of association of resistin with BMI in our study suggests that resistin may influence MM risk through other inflammatory processes. Notably, resistin is also highly expressed in the bone marrow (BM) where it is secreted by osteoclasts and osteoblasts, as well as by monocytes and macrophages (Patel *et al*, 2003). Resistin activates osteoclastogenesis and promotes osteoblast proliferation (Thommesen *et al*, 2006), which suggests a role for resistin in bone remodelling. Considering the interplay between the BM microenvironment and the proliferation of MM cells (Eda *et al*, 2016), impaired resistin expression in the BM niche may induce changes that are favourable to the proliferation of MM cells, which might explain the observed inverse association between resistin and MM risk. Functional analyses in BM tissue could help to clarify the role of resistin and other adipokines in MM pathogenesis.

The strengths of our study include its prospective design and the pooling of data across three cohorts. Limitations include the lack of detailed information on clinical characteristics of MM at diagnosis, as well as information on family history of lymphohaematopoietic malignancies. Given that having a family history of these relatively rare malignancies is uncommon in the general population (Schinasi *et al*, 2016), the potential for confounding by family history is likely to be minimal. However, further investigation in family-based studies and other studies with detailed clinical records may be informative. Finally, although this study is the largest to date that has evaluated the association between resistin and MM, we had limited statistical power for analyses restricted to women, as well as for the cohort-specific and other stratified analyses. Extending this investigation to other prospective cohorts is required to confirm our findings and to better elucidate the differences by sex in the relationship between resistin and MM.

ACKNOWLEDGEMENTS

This work was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute. The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study-II cohort. MNP's laboratory is funded in part by a grant from the Terry Fox Foundation, Vancouver, Canada. The ATBC Study is supported by the Intramural Research Program of the U.S. National Cancer Institute, National Institutes of Health, and by U.S. Public Health Service contract HHSN261201500005C from the National Cancer Institute, Department of Health and Human Services. The MMCC was first established in part with funds from NIH/NCI extramural grants K07 CA115687 (BMB) and R01 CA127435 in addition to the aforementioned support from the NCI Intramural Research Program. BMB is currently supported in part by R21 CA198239.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

- ATBC (1994) The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. *Ann Epidemiol* **4**(1): 1–10.
- Baris D, Brown L, Andreotti G, Devesa S (2013) Epidemiology of multiple myeloma. In: Wiernik P, Goldman J, Dutcher J, Kyle R (eds). *Neoplastic Disease of the Blood*. 5th edn. Springer: New York, NY, USA, pp 547–563.
- Birmann BM, Neuhaus ML, Rosner B, Albanes D, Buring JE, Giles GG, Lan Q, Lee IM, Purdue MP, Rothman N, Severi G, Yuan JM, Anderson KC, Pollak M, Rifai N, Hartge P, Landgren O, Lessin L, Virtamo J, Wallace RB, Manson JE, Colditz GA (2012) Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. *Blood* **120**(25): 4929–4937.
- Calle EE, Rodriguez C, Jacobs EJ, Almon ML, Chao A, McCullough ML, Feigelson HS, Thun MJ (2002) The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. *Cancer* **94**(9): 2490–2501.
- Curat CA, Wegner V, Sengenès C, Miranville A, Tonus C, Busse R, Bouloumie A (2006) Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. *Diabetologia* **49**(4): 744–747.
- Dalamaga M, Karmaniolas K, Panagiotou A, Hsi A, Chamberland J, Dimas C, Lekka A, Mantzoros CS (2009) Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case-control study. *Cancer Causes Control* **20**(2): 193–199.
- Dalamaga M, Sotiropoulos G, Karmaniolas K, Pelekanos N, Papadavid E, Lekka A (2013) Serum resistin: a biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters. *Clin Biochem* **46**(7–8): 584–590.
- Eda H, Santo L, David Roodman G, Raje N (2016) Bone disease in multiple myeloma. *Cancer Treat Res* **169**: 251–270.
- Giles GG, English DR (2002) The Melbourne Collaborative Cohort Study. *IARC Sci Publ* **156**: 69–70.
- Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC (2001) The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. *Oncogene* **20**(33): 4519–4527.
- Hofmann JN, Birmann BM, Teras LR, Pfeiffer RM, Wang Y, Albanes D, Baris D, Colditz GA, De Roos AJ, Giles GG, Hosgood HD, Lan Q, Landgren O, Liao LM, Rothman N, Weinstein SJ, Pollak MN, Neuhaus ML, Purdue MP (2016) Low levels of circulating adiponectin are associated with multiple myeloma risk in overweight and obese individuals. *Cancer Res* **76**(7): 1935–1941.
- Hofmann JN, Liao LM, Pollak MN, Wang Y, Pfeiffer RM, Baris D, Andreotti G, Lan Q, Landgren O, Rothman N, Purdue MP (2012) A prospective study of circulating adipokine levels and risk of multiple myeloma. *Blood* **120**(22): 4418–4420.
- Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS (2003) Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. *J Clin Endocrinol Metab* **88**(10): 4848–4856.
- Lee S, Lee HC, Kwon YW, Lee SE, Cho Y, Kim J, Lee S, Kim JY, Lee J, Yang HM, Mook-Jung I, Nam KY, Chung J, Lazar MA, Kim HS (2014) Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes. *Cell Metab* **19**(3): 484–497.
- Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA (2003) Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. *Biochem Biophys Res Commun* **300**(2): 472–476.
- Rajala MW, Lin Y, Ranalletta M, Yang XM, Qian H, Gingerich R, Barzilay N, Scherer PE (2002) Cell type-specific expression and coregulation of

- murine resistin and resistin-like molecule- α in adipose tissue. *Mol Endocrinol* **16**(8): 1920–1930.
- Reseland JE, Reppe S, Olstad OK, Hjorth-Hansen H, Brenne AT, Syversen U, Waage A, Iversen PO (2009) Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma. *Eur J Haematol* **83**(5): 460–470.
- Schinasi LH, Brown EE, Camp NJ, Wang SS, Hofmann JN, Chiu BC, Miligi L, Beane Freeman LE, de Sanjose S, Bernstein L, Monnereau A, Clavel J, Tricot GJ, Atanackovic D, Cocco P, Orsi L, Dosman JA, McLaughlin JR, Purdue MP, Cozen W, Spinelli JJ, de Roos AJ (2016) Multiple myeloma and family history of lymphohaematopoietic cancers: results from the International Multiple Myeloma Consortium. *Br J Haematol* **175**(1): 87–101.
- Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. *CA Cancer J Clin* **66**: 443–459.
- Teras LR, Kitahara CM, Birmann BM, Hartge PA, Wang SS, Robien K, Patel AV, Adami HO, Weiderpass E, Giles GG, Singh PN, Alavanja M, Beane Freeman LE, Bernstein L, Buring JE, Colditz GA, Fraser GE, Gapstur SM, Gaziano JM, Giovannucci E, Hofmann JN, Linet MS, Neta G, Park Y, Peters U, Rosenberg PS, Schairer C, Sesso HD, Stampfer MJ, Visvanathan K, White E, Wolk A, Zeleniuch-Jacquotte A, de Gonzalez AB, Purdue MP (2014) Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies. *Br J Haematol* **166**(5): 667–676.
- Thommesen L, Stunes AK, Monjo M, Grosvik K, Tamburstuen MV, Kjobli E, Lyngstadaas SP, Reseland JE, Syversen U (2006) Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. *J Cell Biochem* **99**(3): 824–834.
- Tilg H, Moschen AR (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. *Nat Rev Immunol* **6**(10): 772–783.
- Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS (2003) Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. *J Clin Endocrinol Metab* **88**(4): 1730–1736.
- This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

Supplementary Information accompanies this paper on British Journal of Cancer website (<http://www.nature.com/bjc>)